PLx Pharma Inc. to Present Virtually at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
PLx Pharma Inc. (NASDAQ: PLXP) announced that CEO Natasha Giordano and CFO Rita O’Connor will present virtually at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 22, 2020, at 11:40 AM ET. The presentation will be available via live webcast and archived for 30 days on the company’s website. PLx is focused on its VAZALORE™ delivery system, which includes the FDA-approved aspirin capsules designed for improved safety and effectiveness. The company is also working on post-approval data collection for VAZALORE 325 mg and potential approval for VAZALORE 81 mg.
- None.
- None.
SPARTA, N.J., Sept. 14, 2020 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company focused on developing its clinically-validated and patent-protected PLxGuard™ delivery system to provide more effective and safer products, VAZALORE™ 325 mg and VAZALORE™ 81 mg (referred to together as “VAZALORE”™), announced today that Natasha Giordano, President and Chief Executive Officer, and Rita O’Connor, Chief Financial Officer, will present virtually at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit as follows:
| Date: | Tuesday, September 22, 2020 |
| Time: | 11:40 AM Eastern Time |
| Webcast: | https://wsw.com/webcast/oppenheimer5/plxp/2759652 |
The presentation will be webcast live at the aforementioned time, and archived for 30 days thereafter, via the Company’s website at www.plxpharma.com, under the ‘Investors Relations’ Section.
About VAZALORE
VAZALORE 325 mg is an FDA-approved liquid-filled aspirin capsule that provides patients with vascular disease and diabetic patients who are candidates for aspirin therapy with faster, reliable and more predictable platelet inhibition as compared to enteric-coated aspirin, while also reducing the risk of stomach erosions and ulcers, as compared to immediate-release aspirin, common in an acute setting. PLx is focused on collecting the data, including results from a bioequivalence study, required for post-approval manufacturing changes, which will be included in the sNDA filing for VAZALORE 325 mg and to support approval of low dose VAZALORE 81 mg.
About PLx Pharma Inc.
PLx Pharma Inc. is a late-stage specialty pharmaceutical company focused on developing its clinically-validated and patent-protected PLxGuard™ delivery system to provide more effective and safer products. The PLxGuard delivery system works by targeting delivery of active pharmaceutical ingredients to various portions of the gastrointestinal (GI) tract. PLx believes this has the potential to improve the absorption of many drugs currently on the market or in development, and to reduce the risk of stomach erosions and ulcers associated with aspirin and ibuprofen, and potentially other drugs.
To learn more about PLx Pharma Inc. and its pipeline, please visit www.plxpharma.com.
Contact
Investor Relations:
Lisa M. Wilson, In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com
FAQ
When is PLx Pharma's presentation at the Oppenheimer Summit?
Where can I watch the PLx Pharma presentation?
What is VAZALORE from PLx Pharma?
What is the significance of VAZALORE 325 mg for patients?
What are PLx Pharma's plans for VAZALORE 81 mg?
